| Identification | Back Directory | [Name]
BPR1K871 | [CAS]
2443767-35-7 | [Synonyms]
1-(3-Chlorophenyl)-3-(5-(2-((7-(3-(dimethylamino)propoxy)quinazolin-4-yl)amino)ethyl)thiazol-2-yl)urea | [Molecular Formula]
C25H28ClN7O2S | [MDL Number]
MFCD30532626 | [MOL File]
2443767-35-7.mol | [Molecular Weight]
526.05 |
| Chemical Properties | Back Directory | [density ]
1.387±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: 125 mg/mL (237.62 mM) | [form ]
Solid | [pka]
6.12±0.70(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
BPR1K871 is a potent and selective dual FLT3/AURKA inhibitor with IC50s of 19 nM and 22 nM for FLT3 and AURKA, respectively, acts as a preclinical development candidate for anti-cancer therapy[1]. | [in vivo]
BPR1K871 is a multi-kinase inhibitor for the treatment of acute myeloid leukemia (AML) and solid tumors[1].
| [References]
[1] Hsu YC, et al. Discovery of BPR1K871, a quinazoline based, multi-kinase inhibitor for the treatment of AML and solid tumors: Rational design, synthesis, in vitro and in vivo evaluation. 2016 Dec 27; 7(52): 86239–86256. DOI:10.18632/oncotarget.13369 |
|
| Company Name: |
ChemCell Biomedicine Co.,Ltd.
|
| Tel: |
020-13556033878 2965585218 13556033878 |
| Website: |
www.chemicalbook.com/ShowSupplierProductsList15061/0_EN.htm |
| Company Name: |
MedChemExpress
|
| Tel: |
021-58955995 |
| Website: |
www.medchemexpress.com |
|